BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100 that has completed Phase 1 clinical trials is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate, which is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue (BAT). In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
IPO Year:
Exchange: NASDAQ
Website: biorestorative.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/1/2021 | $37.00 | Buy | Roth Capital |
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
MELVILLE, N.Y., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the second quarter June 30, 2024 and provided an update on its business. "We have had an exciting and productive first half of 2004 and are energized by the many potential value enhancing inflection points we see ahead," said Lance Alstodt, BioRestorative's Chief Executive Officer. "From an operating perspective, we are thrilled with our second quarter results, as we are seeing initial progress on our path to sustainable profitab
MELVILLE, N.Y., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it will release its second quarter 2024 financial results after market close on Tuesday, August 13, 2024. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. Second Quarter 2024 Results Conference Call Details: Date:Tuesday, August 13, 2024Time:4:30 p.m. ETDomestic:1-877-545-0523International:1-973-528-0016Access Code:151026 The call will also be broadcast live and a
MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today provided an update on its business. "We have successfully executed against key strategic priorities since the start of the year," said Lance Alstodt, BioRestorative's Chief Executive Officer. "The most important of those were to advance our lead clinical program, BRTX-100, and expand our core preclinical program, ThermoStem®, while also laying the groundwork for our commercial BioCosmeceuticals business to start generating significant revenues this year. We expect that this, combined
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity - MELVILLE, N.Y., April 30, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it will release its first quarter 2024 financial results after market close on Tuesday, May 14, 2024. "I look forward to providing more detail on our exciting recently announced transformative commercial partnership with Cartessa, as well as discussing the meaningful progress we are making with our clinical
— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced the public availability of a poster, presented yesterday at the Orthopaedic Research Society (ORS) 2024 Annual Meeting, which describes preliminary 26 and 52 week blinded data from the ongoing Phase 2 clinical trial of the Company's lead clinical candidate, BRTX-100, in subjects with chronic lumbar disc
— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — — Company to host webcasted conference call to review data on February 5, 2024 at 8:30am EST — MELVILLE, N.Y., Feb. 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that preliminary 26–52 week blinded data from the ongoing Phase 2 clinical trial of BRTX-100 in subjects with chronic lumbar disc disease ("cLDD") will be presented by Francisco Silva, Vice President of Research and Development, at the Orthopaedic Research S
MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Chief Executive Officer, Lance Alstodt, will participate in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024 in New York City. The event will consist of a series of one-on-one investor meetings. To arrange a meeting with BioRestorative, attending investors are encouraged to contact their ROTH MKM sales representative. About BioRestorative Therapies, Inc. BioRestorative (www.biorestorative.com) develops therapeutic p
MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Chief Scientist and Vice President of Research and Development, Francisco Silva, will present at the 21st Annual International Federation for Adipose Therapeutics and Science ("IFATS") Conference being held in Pittsburgh, PA from September 19-22, 2024. Presentation Details Title: Brown Adipose Derived Mesenchymal Stem Cells (BADSCs), a Cell-Based Therapeutic as an Alternative to Glucagon-like Peptide-1 (GLP-1) Agonists to Trea
MELVILLE, N.Y., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the second quarter June 30, 2024 and provided an update on its business. "We have had an exciting and productive first half of 2004 and are energized by the many potential value enhancing inflection points we see ahead," said Lance Alstodt, BioRestorative's Chief Executive Officer. "From an operating perspective, we are thrilled with our second quarter results, as we are seeing initial progress on our path to sustainable profitab
MELVILLE, N.Y., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it will release its second quarter 2024 financial results after market close on Tuesday, August 13, 2024. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. Second Quarter 2024 Results Conference Call Details: Date:Tuesday, August 13, 2024Time:4:30 p.m. ETDomestic:1-877-545-0523International:1-973-528-0016Access Code:151026 The call will also be broadcast live and a
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, is pleased to announce that its Chief Scientist and Vice President of Research and Development, Francisco Silva, has been named Section Editor of the newly launched Regenerative Medicine section of the Journal of Translational Medicine. The Journal of Translational Medicine is a peer-reviewed open-access medical journal which has been published since 2003. According to the Journal Cit
– Adds to comprehensive patent portfolio underlying novel ThermoStem® technology platform – – Expanding intellectual property estate expected to help drive ThermoStem® licensing opportunities – – Substantive discussions continue with commercial stage regenerative medicine company with regard to a license of ThermoStem® IP – MELVILLE, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, is pleased to announce that it has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-564135 related to the Company's all
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, announced that it has received notice from the Nasdaq Stock Market that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) in connection with the filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 with the Securities and Exchange Commission. Summary First Quarter 2024 Results For the quarter ended
- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders – - ThermoStem® is an off-the-shelf platform, well-protected by a comprehensive portfolio of issued patents that cover both the U.S. and international markets – - Potential license partner is a leading commercial stage regenerative medicine company – MELVILLE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today reported that it has had substantive discussions with an undisclosed c
MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York. Management will also be available for one-on-one investor meetings during the conference. About BioRestorative Therapies, Inc. BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to t
MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it received a notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, due to the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (the "Form 10-Q") with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Listing
MELVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Robert Paccasassi has been appointed Vice President of Quality Assurance/Regulatory Compliance. Mr. Paccasassi will lead quality initiatives through the next phase of the Company's growth as patient enrollment is initiated for the Phase 2 clinical trial to treat chronic lumbar disc disease. Mr. Paccasassi has over 25 years of biotech operations and combined experience in Quality Assurance, Regulatory Compliance, and Manufacturing. Prior to joining BioRestorative, Mr. Paccasassi
MELVILLE, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that it has appointed Robert Kristal to the position of Chief Financial Officer. Mr. Kristal brings an extensive array of strategic and financial markets experience to the Company, including a background in advising global public life sciences companies in corporate finance, operations management systems, and strategic collaborations. Mr. Kristal is an experienced and versatile Wall Street and Bay St. professional who has built teams in both institutional sales and equity research at firms which
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13G/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13G/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13G/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13G - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
BioRestorative Therapies, Inc. (NASDAQ:BRTX) shares are trading higher Monday after the company announced it has received notice from the Nasdaq Stock Market that it has regained compliance with listing requirements. The Details: BioRestorative Therapies reported a net loss for the first quarter of $2.2 million, or 33 cents per share, compared to a net loss of $7.2 million, or $1.93 per share, from the same period last year. The company reported a loss from operations of $4.1 million, a 29% improvement from the $5.8 million loss from operations for the comparable period of 2023. The company also reported it ended the first quarter with cash, cash equivalents, and investments held
U.S. stocks traded mixed toward the end of trading, with the S&P 500 edging higher on Thursday. The Dow traded down 0.21% to 38,629.82 while the NASDAQ rose 0.26% to 17,654.01. The S&P 500 also rose, gaining, 0.13% to 5,428.07 . Check This Out: Alphabet, Dropbox And 2 Other Stocks Insiders Are Selling Leading and Lagging SectorsInformation technology shares jumped by 1.1% on Thursday. In trading on Thursday, industrials shares fell by 0.9%. Top Headline Shares of Signet Jewelers Limited (NYSE:SIG) fell around 16% during Thursday’s session following mixed first-quarter earnings including an 8.9% drop in same store sales. The company reported a first-quarter FY25 sales d
Shares of Signet Jewelers Limited (NYSE:SIG) fell sharply during Thursday's session following mixed first-quarter earnings including an 8.9% drop in same store sales. The company reported a first-quarter FY25 sales decline of 9.5% year-on-year to $1.510 billion, missing the analyst consensus estimate of $1.514 billion. Adjusted EPS of $1.11 beat the consensus estimates of 85 cents. Signet expects second-quarter sales of $1.46 billion – $1.52 billion, versus the consensus of $1.508 billion. Signet Jewelers shares dipped 12.5% to $94.81 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers BioRestorative Therapies, Inc. (NASDAQ:BRTX) shares climb
Gainers Longeveron (NASDAQ:LGVN) stock increased by 74.6% to $3.16 during Thursday's regular session. The company's market cap stands at $20.0 million. BioRestorative Therapies (NASDAQ:BRTX) stock rose 27.4% to $1.72. The market value of their outstanding shares is at $11.6 million. Aethlon Medical (NASDAQ:AEMD) shares rose 26.84% to $0.66. The market value of their outstanding shares is at $3.3 million. Sharps Technology (NASDAQ:STSS) stock moved upwards by 23.58% to $0.37. The company's market cap stands at $6.5 million. Biomea Fusion (NASDAQ:BMEA) stock moved upwards by 20.95% to $5.6. The market value of their outstanding shares is at $201.2 million. iSpecimen (NASDAQ:ISPC) shares
U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping by more than 200 points on Thursday. The Dow traded down 0.60% to 38,481.44 while the NASDAQ rose 0.31% to 17,663.22. The S&P 500 also fell, dropping, 0.05% to 5,418.22 . Check This Out: Alphabet, Dropbox And 2 Other Stocks Insiders Are Selling Leading and Lagging SectorsInformation technology shares jumped by 1.2% on Thursday. In trading on Thursday, industrials shares fell by 1.3%. Top Headline Shares of Broadcom Inc. (NASDAQ:AVGO) gained around 13% during Thursday's session after the company posted stronger-than-expected results for its second quarter. The company declared a quarterly d
BioRestorative Therapies, Inc. (NASDAQ:BRTX) shares are trading higher Thursday after the company said it has engaged in licensing discussions with a undisclosed commercial regenerative medicine company. What Happened: BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions with an regenerative medicine company related to its ThermoStem Metabolic Disease Program intellectual property. Research conducted in collaboration with the University of Utah School of Medicine has demonstrated that certain stem cells with brown adipogenic potential could represent a new way of treating obesity and related metabolic disorders.
U.S. stocks traded mixed this morning, with the Dow Jones index falling by more than 100 points on Thursday. Following the market opening Thursday, the Dow traded down 0.36% to 38,574.00 while the NASDAQ rose 0.55% to 17,705.52. The S&P 500 also rose, gaining, 0.19% to 5,431.23. Check This Out: Alphabet, Dropbox And 2 Other Stocks Insiders Are Selling Leading and Lagging SectorsInformation technology shares jumped by 1.4% on Thursday. In trading on Thursday, communication services shares fell by 0.9%. Top Headline U.S. producer prices fell by 0.2% month-over-month in May versus market estimates of a 0.1% gain and following a 0.5% increase in April. Equities Trading UP
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
Roth Capital initiated coverage of BioRestorative Therapies with a rating of Buy and set a new price target of $37.00
8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
10-Q - BioRestorative Therapies, Inc. (0001505497) (Filer)
8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
DEF 14A - BioRestorative Therapies, Inc. (0001505497) (Filer)
8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
10-Q - BioRestorative Therapies, Inc. (0001505497) (Filer)
10-K/A - BioRestorative Therapies, Inc. (0001505497) (Filer)
8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
NT 10-Q - BioRestorative Therapies, Inc. (0001505497) (Filer)